Polypill Prevention Trial 1

Completed

• Conditions: Cardiovascular Disease; Circulatory System

• Registration Number: ISRCTN36672232
• Lead Sponsor: Queen Mary University of London (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2011-04-15
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Men and women aged 50 and over, without selection on the basis of other risk factors, for whom there is no medical contra-indication to taking the Polypill

Exclusion Criteria

1. Clinical history of cardiovascular disease
2. Any illness judged to contra-indicate participation in the trial
3. Taking other specified drugs: lithium, cyclosporine or other calcineurin inhibitors, erythromycin or other macrolides, azole antifungals, ritonavir or other protease inhibitors, amiodarone

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Serum cholesterol<br>2. Systolic blood pressure<br>3. Diastolic blood pressure<br>Outcomes assessed at the end of each 12 week treatment period

Secondary Outcome Measures

Name	Time	Method
1. Adverse effects<br>2. Adherence